Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer. (2016). ADMET and DMPK, 4(4), 314-326. https://doi.org/10.5599/admet.4.4.341